Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + melphalan vs melphalan as conditioning before autologous HSCT in multiple myeloma
ChiCTR2100043720Phase 4Recruiting
- Sponsor
- Department of Hematology and Oncology, Chongqing University Cancer Hospital
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in multiple myeloma (MM) comparing bendamustine + melphalan conditioning with melphalan alone conditioning (2 arms). Primary endpoint: Minimal residual disease negative rate. Started Mar 2021; status: recruiting.
02
Drugs
bendamustinemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100043720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043720.